Genmab Acquires ProfoundBio: Accelerating Innovation in Antibody-based Therapeutics

ProfoundBio, now an integral part of Genmab, is thrilled to announce a substantial funding achievement, securing a remarkable $112 million to propel forward its mission in the biopharmaceutical landscape.

As we integrate into Genmab’s innovative ecosystem, this investment not only underscores the strong faith stakeholders have in our vision but also amplifies our capacity to develop groundbreaking antibody-based therapeutics tailored for cancer patients.

The critical funding will be strategically allocated to advance our ongoing research initiatives, enhance our clinical development programs, and accelerate the commercialization of promising therapeutic candidates.

Our commitment to transforming the treatment paradigm for cancer patients remains unwavering, and with Genmab’s resources and expertise, we are excited to broaden our impact on patient care.

In an era where precision medicine is becoming increasingly paramount, the synthesis of our cutting-edge research and Genmab’s robust platform is poised to yield novel solutions that address unmet medical needs effectively.

As we transition into this new chapter, we encourage our valued partners, stakeholders, and the scientific community to stay updated on our progress.

Thank you for your continued support as we embark on this journey of innovation and patient-centric solutions.

For the latest news and developments in our therapeutic endeavors, please follow Genmab at https://bit.ly/3Kf80df, as this page will no longer be active or monitored.

Together, we aspire to make a meaningful difference in the lives of cancer patients globally.